
Conference Coverage
about 1 month ago
NeuroOp Guru at AAO 2026: Blurry vision in MS isn’t always a relapseabout 1 month ago
AAO 2026: Rethinking dry eye as a spectrum of ocular painabout 1 month ago
AAO 2026: Preventing complications in uveitic cataract surgeryabout 1 month ago
AAO 2026: Setting realistic expectations with refractive IOLsabout 1 month ago
AAO 2026: Comprehensive ophthalmologists are the uveitis front lineTrending on the Eye Care Network
Water-soluble CBD eye drops lower IOP and dampen corneal sensitivity in glaucoma mouse model
BL1332 misses primary end point in phase 2 post-PRK ocular pain study
FLORetina-ICOOR 2026: AI moves from the image to the trial, the clinic, and the operating room
Why ST-100 is expanding from dry eye into corneal wound healing
Dry eye and Sjögren disease: Esen Akpek, MD, on screening and referral
Latest News

FLORetina-ICOOR 2026: FLO-ROP pathway brings ROP and pediatric retina to FLORetina 2026

BL1332 misses primary end point in phase 2 post-PRK ocular pain study

Dry eye and Sjögren disease: Esen Akpek, MD, on screening and referral

FLORetina-ICOOR 2026: AI moves from the image to the trial, the clinic, and the operating room

Q&A: GLP-1 RAs and NAION, the case for a baseline exam

Shorts










Digital Edition




Podcasts
Continuing Medical Education
All News

The phase 2 EMERALD trial compares 2 doses of EO2002 with placebo, with a 15-letter BCVA gain at 26 weeks as the primary end point.

A hydrophilic topical cannabidiol formulation produced a sustained, largely local IOP reduction in DBA/2J mice with chronic dosing, adding a new wrinkle to one of glaucoma’s longest-running debates.

A longer axial length in the fellow eye of that treated for a rhegmatogenous retinal detachment was associated with a greater risk of a total retinal detachment.

Polygenic risk scores predicted glaucoma onset and treatment course better than family history alone in a 400,000-person biobank.

A structure-first approach to blepharoplasty and filler yields more durable, natural results.

The agreement brings J&J a next-generation bispecific antibody that outpaced faricimab on early anatomic measures in the phase 1b JADE trial, with Blackstone Life Sciences committing $750 million to fund phase 3 development.

A systemic Sjögren therapy would make earlier identification more actionable for ophthalmologists, Esen K. Akpek, MD, said.

Veeral S. Sheth, MD, MBA, FACS, FASRS, discusses the evidence behind the new labeling requirement and how it aligns with the AAO/NANOS consensus statement.

Two cases highlight when to start therapy in extensive and early atrophy

The half-life extended FcRn inhibitor showed a 74% peak reduction in IgG in healthy volunteers.

The agency concluded that GLP-1 receptor agonists carry a potential increased risk of the rare optic neuropathy and is adding it to the Warnings and Precautions section of every product's label.

Kiril Kiprovski, MD, of NYU Langone shares clinical clues and bedside tests for spotting Lambert-Eaton myasthenic syndrome.

MyoSpectrumNet pulls 3 public fundus datasets into 1 multi-output framework. Screening and grading accuracy held up against dedicated models, but the authors are open about where joint learning gave ground.
























